The HRSA/SPNS Hepatitis C Treatment Expansion Initiative: Project Summary Webinar for Demonstration Clinics.

Slides:



Advertisements
Similar presentations
Preparing for Direct Acting Antivirals (DAAs) in PracticeNew Paradigms in the Management of HCV Sherilyn C. Brinkley, MSN, CRNP Nurse Practitioner/Program.
Advertisements

Delaware Telehealth Coalition Winter 2014 Meeting 1.
Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.
Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.
HCV: Treat now or Defer Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL JUNE 19,
Clinical managment of hepatitis C in an environment with limited acces to treatment Andrzej Horban Hospital of Infectious Diseases Warsaw, Poland.
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
Global Hepatitis C Guidelines 2014: recommendations for a public health approach Gottfried Hirnschall.
Integrating and Paying for CHWs in Emerging Models of Care Health System Model Perspective The HIV Experience.
Managing Hepatitis C: An Unprecedented Correctional Healthcare Challenge ASCA/CCHA meeting Phoenix, AZ RADM Newton E. Kendig Assistant Director/Medical.
Benton Community Health Center Located at: 530 NW 27 th Street Corvallis, Oregon (inside the Public Services building) Medical Staff consists of: 3 Physicians.
Family Medicine Residency of Idaho HIV Training Track.
Abstract Results Objectives Results Conclusions Background Methods V-1637 Background-At the CORE center in Chicago, despite an on-site hepatitis clinic.
HEPATITIS C TREATMENT EXPANSION INITIATIVE ETAC Project Summary Webinar May 28, 2014 The HRSA/SPNS Hepatitis C Treatment Expansion Initiative: Project.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Management of Chronic HCV Infection by PMDs Rod Rahimi Osler Journal Club
ALAN FRANCISCUS EXECUTIVE DIRECTOR, HEPATITIS C SUPPORT PROJECT EDITOR-IN-CHIEF, HCV ADVOCATE WEBSITE JOIN ME ON TWITTER & FACEBOOK – HCVADVOCATE BLOG:
Co-occurring Challenges: Leveraging ADAP and ACA to Address Hepatitis C and Substance Use Disorders Daniel Raymond Policy Director Harm Reduction Coalition.
Summary of ICIUM Chronic Care Track Prepared by: Ricardo Perez-Cuevas Veronika Wirtz David Beran.
Twice Weekly Peg-IFN-alpha-2a with Ribavirin Improves Early Viral Kinetics over Standard Therapy Among HIV/HCV Co-Infected African American Patients Alison.
Ryan White All Grantees Meeting Washington, DC November, 2012 Supporting National HIV/AIDS Strategies: the domestic experience and the AETCs.
Suppressing the Hepatitis C virus, Barriers to Care American Public Health Association APHA 143 rd Annual Meeting&Expo October 31-November 4,2015, Chicago,
FDA Hepatitis C Hearing Oct 19, 2006 Jules Levin Executive Director/Founder, NATAP National AIDS Treatment Advocacy Project.
Bringing Hepatitis C Treatment into the Medical Home A Pilot Program for Drug Users Dr. Joanna Eveland MS, MD, Clinical Chief for Special Populations Mission.
Hepatitis C Needs Assessment: Contributions from the National HCV Diagnosis and Local Clinical Databases.
1 Center Mission Statements SAMHSA ? CSAT Improving the Health of the Nation by Bringing Effective Alcohol and Drug Treatment to Every Community CMHS Caring.
Hepatitis C Past, present and future Salil Singh Consultant Gastroenterologist, RBH
Non-Medical Staff Knowledge, Beliefs and Practices about HIV and Hepatitis for Injection Drug Users Rowe, KA 1, Tesoriero, JM 1, Heavner, KK 1, Rothman,
The Reduction of Emergency Room Visits for Non- Emergent Health Concerns in Bakersfield, California Mariah Walton, MPH Public Health Advisor Office for.
Phase 3 Treatment Experienced
Clinical Quality Improvement: Achieving BP Control
For Official Use Only-I1-A1
Where Are We on the Path to Elimination of Chronic Hepatitis C?
EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.
Lesson 2: Special Considerations When Treating HIV/HCV Co-infection
Classification of virologic responses based on outcomes during and after a 48-week course of pegylated interferon (PEG IFN) plus ribavirin antiviral therapy.
Effectiveness of Sofosbuvir in terms of sustained virological response at 12 weeks after treatment (SVR12) BETWEEN treatment naïve AND treatment.
Addressing the Intersection of Substance Abuse and Viral Hepatitis
Phase 3 Treatment-Naïve and Treatment-Experienced
Objectives of behavioral health integration in the Family Care Center
Presentation Developed for the Academy of Managed Care Pharmacy
Treatment Outcomes for Chronic Hepatitis C Infection with Direct Acting Antivirals among Inmates in Federal Corrections Smith JM, Boudreau H, Kom E, Tremblay.
Lesson 4: Test Your Knowledge
Older peoples services
A. Stepanov, A. Kruk, N. Polovinkina, A. Vinogradova
Lesson 4: Test Your Knowledge
Cherokee Nation Health Services HCV Elimination Program
THE APP THAT ALLOWS EVERY DOCTOR TO PRACTICE:
Hepatitis B and C management pathways in prison:
HIV/HCV Co-Infection Case
DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?
Core Competency 4: HCV Treatment
LEAGUE-1 study: daclatasvir + SMV + RBV for genotype 1
Talking to Patients About HCV Treatment
Chronic Hepatitis C Virus Infection
Health Home Program Services for Patient 1st Medicaid Recipients
Health Home Program Services
Providing sustainable resilient primary care
Simeprevir in HIV Coinfection, GT-1 C212 Trial
Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I
How are PHNs Personalising the Mental Health System?
Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2
Treat first! Shade says…
Blood borne viral hepatitis action in Wales
Professor Jack Lambert
Prism Health North Texas Programs and Services
Lesson 2: Special Considerations When Treating HIV/HCV Co-infection
Design Randomisation * 2 : 1 Double blind W12 W16 W24 W28
Lesson 3: The HCV Care Continuum
Hepatitis C Testing, Treatment, Care and Support
Presentation transcript:

The HRSA/SPNS Hepatitis C Treatment Expansion Initiative: Project Summary Webinar for Demonstration Clinics

ONGOING HCV/HIV RESOURCES

Resources - www.usfetac.com

Tools & Forms See ETAC website: http://health.usf.edu/medicine/internalmedicine/infectious/etac/index.htm Side bar link: Tools and Forms Consent for Hepatitis C Treatment ISU Decision flow chart ISU HCV tracker for patients st mary WashingtonUniv_H97HA19759_Appendix2-patient monitoring UCSF_Protocol_for_Circle_of_care_5_18_12_final.pdf

Web Based Resources http://aasld.org/PRACTICEGUIDELINES/Pages/guidelinelisting.aspx Hepatitis C, Guidance and Hepatitis C, management and treatment http://aasld.org/LiverLearning%C2%AE/Pages/HCVtalks2.aspx Learning site for special populations. http://aasld.org/LiverLearning%C2%AE/Pages/LiverProgramforPrimaryCareProviders.aspx Modular training with free CME for Hepatitis B and Hepatitis C http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf EASL Recommendations on Treatment of Hepatitis 2014

Web Based Resources www.medscape.com/hiv Requires registration. Search on this site for HIV/HCV https://www.clinicaloptions.com/Hepatitis or/HIV Both sites have slides and CME education related to the coinfected patient 2014 - Optimal Management of HIV and Hepatitis: Clinical Conference XXII http://www.practicepointhepatitis.com/

ECHO/TELEHEALTH http://echo.unm.edu/ http://fcaetc.org/echo Univ. of NM TeleECHO clinics offers HCV monoinfection & HIV sessions http://fcaetc.org/echo USF Florida/Caribbean AETC ECHO offers HIV/HCV and General HIV sessions http://depts.washington.edu/nwaetc/echo/index.html NW AETC ECHO home offers HIV sessions

SUSTAINABILITY

Program Components Clinic Infrastructure Personnel Delivery Protocols Resources

Clinic Infrastructure Established clinic with stable personnel Diverse service availability Organization leadership 340-B pharmacy Availability of clinical trials Access to specialists Access to HCV rapid testing Established outreach programs

Personnel Experienced providers Affiliated specialists Dedicated case managers Dedicated HCV nurses Dedicated pharmacists Mental health/ substance abuse specialists Specific personnel in some sites

Delivery Protocols Established treatment protocols Quality improvement activities

Resources Ryan White Care Act Mixed payer source New drug availability Local public health authority Patient assistance programs Tele-Health activities

PROJECT FINDINGS

Patient Gender Female Male Transgender Total HCV+ Patients at baseline   Female Male Transgender Total HCV+ Patients at baseline 1370 3697 94 5161 % of patients 26.6% 71.6% 1.8% Patients treated 41 196 2 239 % of patients treated 17.2% 82.0% .8%

Patient Race/Ethnicity   African American Asian White Other/ Unknown Total Hispanic HCV+ Patients at baseline 2468 60 1367 1266 5161 1224 % of patients 47.8% 1.2% 26.5% 24.5% 23.7% Patients treated 86 3 121 29 239 76 % of patients treated 36.0% 1.3% 50.6% 12.1% 31.8

Models of care Model 1: Integrated care – no clinic Model 2: Integrated care with clinic Model 3: Primary care – Expert Backup Model 4: Co-located care with specialist

Patients treated by model of care   model 1 model 2 model 3 model 4 Patients treated 64 118 43 14 clinics 10 7 5 patients/clinic 6.4 16.9 6.1 2.8 HCV+ patients 2039 1996 736 390 Treated/HCV+ 3.14% 5.92% 5.84% 3.59% Total treated patients / Total HCV+ patients at baseline = 4.63%

Patients treated by model and year   model 1 model 2 model 3 model 4 year 1 24 48 16 6 year 2 37 53 23 7 year 3 3 17 4 1 patients 64 118 43 14 clinics 10 5 patients/clinic 6.4 16.9 6.1 2.8

Patients treated by study cohort   cohort 1 cohort 2 total year 1 46 48 94 year 2 66 54 120 year 3 25 137 102 239

Size Matters Small (<1,000 HIV+ pts) Large (>1,000 HIV+ pts)   Small (<1,000 HIV+ pts) Large (>1,000 HIV+ pts) Patients treated 71 168 clinics 15 14 patients/clinic 4.73 12.00 HCV+ patients 1,032 4,129 Treated/HCV+ 6.88 4.07

Genotype of patients treated 1 191 2 18 3 21 4 Other/unknown 7

Treatment for Genotype 1 patients Standard (Interferon + Ribavirin) 74 Telapravir (Incivek) 84 Boceprevir (Victrelis) 22 Experimental 9 Unknown 2

Patient Outcomes Patients Number Started treatment 239 Terminated early 94 Completed with viral suppression 100 Completed but relapsed 5 Unknown outcomes 40 Treatment success rate % of patients who started: 41.8% % of patients with known outcomes: 50.2%

Early Termination: When? Time in treatment Patients First 12 weeks 51 12 – 24 weeks 30 24 – 48 weeks 13

Early Termination: WHO?   0 -12 weeks 12-24 weeks 24-48 weeks total % of treated patients male 38 23 10 71 36.2% female 12 6 3 21 51.2% transgender 1 2 100.0% 51 30 13 94 39.3% afr amer 37 43.0% white 44 36.4% other 7 5 44.8% 39.5%

Early Termination: Why? Reason   Patients   Physical adverse effects 36 Psychological adverse effects 7 Patient request 4 Patient lost 3 Alcohol use 2 Insufficient treatment response 33 Other 9 Total early termination  94

Patients terminating treatment early by genotype   0 -12 weeks 12 – 24 weeks 24 – 48 weeks total % of treated patients Genotype 1 44 24 10 78 40.8% Genotype 2 2 6 33.3% Genotype 3 3 1 7 Genotype 4 50.0% Other/unknown 28.6%

Genotype 1 Patient outcomes Treatment # patients SVR Early termination Relapse Unknown Standard 74 35 34 2 3 Telaprivir 84 29 1 25 Boceprivir 22 6 13 Experimental 9 Total 191 77 78 33

Genotype 1 Patients: Termination Reason by Treatment   Physical adverse effects Psychological adverse effects Insufficient treatment response Other Standard 9 2 18 5 Telapravir 13 3 8 Boceprevir 1 Experimental Unknown

Early termination by model of care   0 -12 weeks 12-24 weeks 24-48 weeks total % of treated patients Model 1 12 3 27 43.2% Model 2 29 7 48 40.7% Model 3 8 4 1 13 30.2% Model 4 2 6 42.9%

Barriers to treatment: Administrative/Financial Changing leadership means persuading new people Changing staff means training new people Scheduling challenges Extra paperwork – prior authorizations Inadequate insurance coverage for procedures

Barriers to treatment: Community Lack of highly skilled nursing and pharmacy staff Lack of mental health treatment resources Lack of substance abuse treatment resources

Barriers to treatment: Patient resistance Patients have many complex and competing priorities Many patients have heard negative stories about the side effects Patient refusal was more often due to timing than unwillingness

Barriers to treatment: Poor treatment options Clinician resistance Patient resistance Patients’ acute and chronic mental health issues

FUTURE CHALLENGES

Clinic Infrastructure/Personnel How much of each clinics’ HCV treatment program was designed to address challenges with interferon based therapy? Workforce realignment: Can personnel who were working to address a high toxicity/low efficacy paradigm (high patient needs) shift to address a low toxicity/high efficacy era (high patient volume)?

Moving forward… Change in reimbursement structure Affordable Care Act New HCV treatment guidelines Newly approved DAAs

Changes in Reimbursement/Drug Funding New limitations on DAAs based on liver disease severity Some drugs limited to only fibrosis grades 3 or above Role of consultants in an ACO Clinic-based treatment decisions at provider level versus higher volume review by a dedicated specialist

New HCV/HIV Treatment Guidelines Each newly released direct acting antiviral must be evaluated and proper role in treatment established Efficacy is now high across multiple classes New Questions? Timing – how to stratify multiple eligible patients for treatment now or later Cost Drug Interactions

Timing of Therapy Quickly entering an interferon and ribavirin free era of HCV treatment Who truly needs treatment now and who can wait for better, more tolerable therapies? Are current therapies good enough so that clinicians can stop waiting and can proceed with patient treatment?